These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 24419412

  • 21. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE.
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [Abstract] [Full Text] [Related]

  • 22. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R.
    J Clin Oncol; 2015 Mar 20; 33(9):1008-14. PubMed ID: 25667291
    [Abstract] [Full Text] [Related]

  • 23. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 20; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 24. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
    Tenuta A, Klotz L, Parker JL.
    BJU Int; 2014 May 20; 113(5b):E82-9. PubMed ID: 24053150
    [Abstract] [Full Text] [Related]

  • 25. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct 20; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 26. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J, Hirsch FR, Li Q, Page RD.
    Lung Cancer; 2015 May 20; 88(2):223-30. PubMed ID: 25804732
    [Abstract] [Full Text] [Related]

  • 27. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J.
    Clin Ther; 2005 Oct 20; 27(10):1513-34. PubMed ID: 16330289
    [Abstract] [Full Text] [Related]

  • 28. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F, Shi Y, Wang Y, Ding L, Yuan X, Sun Y.
    Future Oncol; 2015 Oct 20; 11(3):385-97. PubMed ID: 25675121
    [Abstract] [Full Text] [Related]

  • 29. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
    Solomon B, Wilner KD, Shaw AT.
    Clin Pharmacol Ther; 2014 Jan 20; 95(1):15-23. PubMed ID: 24091716
    [Abstract] [Full Text] [Related]

  • 30. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
    Gautschi O, Schefer H, Riklin C, Strobel K, Diebold J.
    Onkologie; 2013 Jan 20; 36(6):342-7. PubMed ID: 23774148
    [Abstract] [Full Text] [Related]

  • 31. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R.
    J Natl Cancer Inst; 2005 Feb 16; 97(4):249-50. PubMed ID: 15713955
    [No Abstract] [Full Text] [Related]

  • 32. Biomarker-driven adjuvant targeted therapy for NSCLC-the ALCHEMIST trials.
    Oxnard GR, Watt C, Wigle D, Boughey JC.
    Bull Am Coll Surg; 2015 Sep 16; 100(9):25-7. PubMed ID: 26455072
    [No Abstract] [Full Text] [Related]

  • 33. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ, Ou SH.
    Chin Clin Oncol; 2015 Jun 16; 4(2):20. PubMed ID: 26112806
    [Abstract] [Full Text] [Related]

  • 34. The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.
    Vrancken A, Lepers S, Peeters L, Oyen C, Dooms C, Nackaerts K, Verbeken E, Wauters I, Weynand B, Vansteenkiste J.
    Lung Cancer; 2016 Dec 16; 102():96-100. PubMed ID: 27987596
    [Abstract] [Full Text] [Related]

  • 35. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R, Kolesar JM.
    J Oncol Pharm Pract; 2012 Jun 16; 18(2):271-4. PubMed ID: 21844131
    [Abstract] [Full Text] [Related]

  • 36. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
    Gadgeel SM, Ivy P, Chen W, Mauer J, Smith D, Lorusso P.
    Clin Lung Cancer; 2011 Jul 16; 12(4):218-23. PubMed ID: 21726820
    [Abstract] [Full Text] [Related]

  • 37. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ.
    J Thorac Oncol; 2011 Sep 16; 6(9):1474-80. PubMed ID: 21642865
    [Abstract] [Full Text] [Related]

  • 38. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
    Reungwetwattana T, Weroha SJ, Molina JR.
    Clin Lung Cancer; 2012 Jul 16; 13(4):252-66. PubMed ID: 22154278
    [Abstract] [Full Text] [Related]

  • 39. Tissue sampling in lung cancer: a review in light of the MERIT experience.
    Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J.
    Lung Cancer; 2011 Oct 16; 74(1):1-6. PubMed ID: 21658788
    [Abstract] [Full Text] [Related]

  • 40. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R.
    Clin Cancer Res; 2005 Sep 15; 11(18):6414-21. PubMed ID: 16166415
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.